BR0314172A - Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado - Google Patents

Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado

Info

Publication number
BR0314172A
BR0314172A BR0314172-1A BR0314172A BR0314172A BR 0314172 A BR0314172 A BR 0314172A BR 0314172 A BR0314172 A BR 0314172A BR 0314172 A BR0314172 A BR 0314172A
Authority
BR
Brazil
Prior art keywords
compound
conjugate
composition
water
hydrate
Prior art date
Application number
BR0314172-1A
Other languages
English (en)
Inventor
Antoni Kozlowski
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Publication of BR0314172A publication Critical patent/BR0314172A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/198—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Abstract

"POLìMERO SOLúVEL EM áGUA, FORMA DE HIDRATO OU ACETAL, COMPOSTO, CONJUGADO, COMPOSIçãO, USOS DO COMPOSTO E DO CONJUGADO, E, PROCESSO PARA PREPARAR O CONJUGADO". A presente invenção está direcionada aos derivados de alcanal de polímeros solúveis em agua tais como poli(etileno glicol), seus hidratos e acetais correspondentes e aos métodos para preparar e usar tais alcanais poliméricos. Os alcanais poliméricos da invenção são preparados em alta pureza e exibem estabilidade na armazenagem.
BR0314172-1A 2002-09-09 2003-09-09 Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado BR0314172A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40925102P 2002-09-09 2002-09-09
US45658003P 2003-03-19 2003-03-19
PCT/US2003/028221 WO2004022630A2 (en) 2002-09-09 2003-09-09 Water-soluble polymer alkanals

Publications (1)

Publication Number Publication Date
BR0314172A true BR0314172A (pt) 2005-07-26

Family

ID=31981629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314172-1A BR0314172A (pt) 2002-09-09 2003-09-09 Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado

Country Status (22)

Country Link
US (5) US7157546B2 (pt)
EP (1) EP1546235B1 (pt)
JP (2) JP4764630B2 (pt)
KR (2) KR20050093856A (pt)
AP (2) AP2005003249A0 (pt)
AU (1) AU2003270454B2 (pt)
BR (1) BR0314172A (pt)
CA (1) CA2498167C (pt)
EA (1) EA200500475A1 (pt)
EC (1) ECSP055654A (pt)
ES (1) ES2897470T3 (pt)
GE (1) GEP20074193B (pt)
HR (2) HRP20050319A2 (pt)
IS (1) IS7789A (pt)
MA (1) MA27401A1 (pt)
MX (1) MXPA05002620A (pt)
NO (2) NO20051078L (pt)
NZ (2) NZ538624A (pt)
PL (1) PL375883A1 (pt)
RS (2) RS20050202A (pt)
UA (1) UA80838C2 (pt)
WO (1) WO2004022630A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
KR100964411B1 (ko) 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US7157546B2 (en) 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
PL217085B1 (pl) 2002-09-11 2014-06-30 Fresenius Kabi Gmbh Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania koniugatu hydroksyalkiloskrobi i polipeptydu, zastosowanie koniugatu hydroksyalkiloskrobi i polipeptydu oraz kompozycja farmaceutyczna koniugatu hydroksyalkiloskrobi i polipeptydu
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
SG145746A1 (en) * 2003-08-08 2008-09-29 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and g-csf
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005092391A2 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DE202005021885U1 (de) * 2004-03-11 2011-03-03 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt
KR101276422B1 (ko) 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
US20050215710A1 (en) * 2004-03-23 2005-09-29 Gegg Colin V Jr Chemically modified protein compositions and methods
CA2573262C (en) * 2004-07-16 2015-02-10 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
EP1807436B1 (en) * 2004-10-25 2014-06-18 Intezyne Technologies Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
WO2009099670A2 (en) 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
KR100967833B1 (ko) * 2008-05-20 2010-07-05 아이디비켐(주) 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법
JP5639585B2 (ja) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
JP5766118B2 (ja) 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
US9139633B2 (en) 2009-07-14 2015-09-22 Novartis Ag Mesenchymal stem cell differentiation
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US8765113B2 (en) 2011-06-27 2014-07-01 Greatbatch Ltd. Peptide based antimicrobial coating
EP2592103A1 (en) * 2011-11-08 2013-05-15 Adriacell S.p.A. Polymer aldehyde derivatives
JP5999659B2 (ja) * 2011-12-14 2016-09-28 国立大学法人 筑波大学 新規分岐ポリエチレングリコール及びその用途
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JP6106104B2 (ja) 2014-01-16 2017-03-29 信越化学工業株式会社 末端にアミノ基を有する狭分散ポリアルキレングリコール誘導体の製造方法
JP6106103B2 (ja) * 2014-01-16 2017-03-29 信越化学工業株式会社 末端にアミノ基を有する狭分散ポリアルキレングリコール誘導体の製造方法、並びにこれに用いる新規なアセタール基含有アルコール化合物及びそのアルカリ金属塩
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5695142A (en) * 1979-12-28 1981-08-01 T Hasegawa Co Ltd Preparation of aliphatic aldehyde
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
JPH04502011A (ja) 1988-11-23 1992-04-09 ジェネンテク，インコーポレイテッド ポリペプチド誘導体
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JPH06233816A (ja) 1993-02-12 1994-08-23 Toyobo Co Ltd 血液浄化吸着材
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5627662A (en) * 1994-04-28 1997-05-06 Xerox Corporation Digital imaging system using two-dimensional input sensor array and output light valve
FR2724459B1 (fr) 1994-09-14 1997-05-09 Univ Compiegne Tech Electrophorese capillaire d'affinite, matrice d'affinite pour la mise en oeuvre de cette electrophorese et son procede de fabrication
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JPH11322916A (ja) 1998-05-11 1999-11-26 Kazunori Kataoka ビオチン残基を片末端に有するヘテロテレケリツクポリマー
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
AU1325400A (en) * 1998-10-26 2000-05-15 University Of Utah Research Foundation Method for preparation of polyethylene glycol aldehyde derivatives
AU2346900A (en) 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
JP2000303090A (ja) * 1999-04-20 2000-10-31 T Hasegawa Co Ltd 香料組成物
ATE317868T1 (de) * 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
CN1608079A (zh) 2001-11-20 2005-04-20 法玛西雅公司 化学修饰的人生长激素缀合物
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) * 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100964411B1 (ko) 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
AU2003235142A1 (en) * 2002-04-26 2003-11-10 Gp Daikyo Corporation Sound absorbing body, sound absorbing structural body, and method of manufacturing these bodies
PL214871B1 (pl) 2002-07-24 2013-09-30 Hoffmann La Roche Pochodne aldehydowe glikolu polietylenowego, zwiazki posrednie oraz sposób wytwarzania pochodnych aldehydowych glikolu polietylenowego
US7157546B2 (en) * 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US6961962B1 (en) * 2004-09-09 2005-11-08 Morning Pride Manufacturing, L.L.C. Combined closure and liner zippers employing common zipper tapes and protective garment employing said combined zippers
JP5084245B2 (ja) 2006-06-07 2012-11-28 関西ペイント株式会社 澱粉系塗料組成物

Also Published As

Publication number Publication date
NO20051077L (no) 2005-04-08
US20090234070A1 (en) 2009-09-17
US7838595B2 (en) 2010-11-23
PL375883A1 (en) 2005-12-12
JP2005350470A (ja) 2005-12-22
US20110034737A1 (en) 2011-02-10
AU2003270454B2 (en) 2010-05-20
AP2005003246A0 (en) 2005-03-31
RS20050202A (en) 2007-08-03
MA27401A1 (fr) 2005-06-01
IS7789A (is) 2005-04-08
WO2004022630A3 (en) 2004-04-15
NZ540490A (en) 2007-10-26
CA2498167C (en) 2012-03-20
US8076412B2 (en) 2011-12-13
EP1546235B1 (en) 2021-10-20
EA200500475A1 (ru) 2005-10-27
US7511094B2 (en) 2009-03-31
WO2004022630A2 (en) 2004-03-18
UA80838C2 (en) 2007-11-12
HRP20050320A2 (en) 2006-12-31
AP2005003249A0 (en) 2005-03-31
ES2897470T3 (es) 2022-03-01
KR20050093856A (ko) 2005-09-23
MXPA05002620A (es) 2005-05-05
GEP20074193B (en) 2007-09-10
JP2005538224A (ja) 2005-12-15
US20120065429A1 (en) 2012-03-15
US7157546B2 (en) 2007-01-02
US20040116649A1 (en) 2004-06-17
CA2498167A1 (en) 2004-03-18
KR100974843B1 (ko) 2010-08-11
EP1546235A2 (en) 2005-06-29
KR20050057281A (ko) 2005-06-16
AU2003270454A1 (en) 2004-03-29
NO20051078L (no) 2005-04-08
JP4764630B2 (ja) 2011-09-07
RS20050203A (en) 2007-08-03
NZ538624A (en) 2007-01-26
ECSP055654A (es) 2005-05-30
HRP20050319A2 (en) 2006-12-31
US20060194940A1 (en) 2006-08-31
US8853325B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
BR0314172A (pt) Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
BRPI0418309B8 (pt) "géis coesos de hialuronado e/ou hilano reticulados, processo para a preparação dos mesmos, bem como composições e dispositivos compreendendo os referidos géis".
EP2256175B1 (en) Viscoelastic cationic carbohydrate ether compositions
BR9802609A (pt) Composição, e, processo para preparar um polìmero hase neutralizado.
BR0113496A (pt) Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica
BRPI0507094A (pt) métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo
BR0108841A (pt) Derivado de pirimidina, processo para prepapar o mesmo, composição farmacêutica, uso de um derivado de pirimidina, e, método para produzir um efeito inibidor do ciclo celular, antic ncer (anti-proliferação celular) em um animal de sangue quente
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
BRPI9907084B8 (pt) processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável
BR9907968B1 (pt) composição de polìmeros com memória de formato biodegradáveis e artigos compreendendo a mesma.
BR0207502A (pt) Compostos, enanciÈmeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
ATE327287T1 (de) Formgedächtnis-polymer
BR9813715A (pt) Composição de polìmeros absorventes permutadores de ìons misturados no leito, elemento absorvente e artigo absorvente
DE602004019488D1 (de) Hyaluronsäurederivat mit einer Urethanbindung
BR0107770A (pt) Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas
ATE235240T1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
CO5251382A1 (es) Derivados de aminometil-fenil-ciclohexano sustituidos, procedimiento para su preparacion, su uso para la preparacionb de medicamentos y medicamentos que contienen estos compuestos
BR0013694A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma
BR0115119A (pt) Derivados tricìclicos de indol com atividade antiangiogênica
WO2009020029A1 (ja) 感放射線性樹脂組成物
IT1318467B1 (it) Processo per la sintesi di cefoperazone sodico ad elevatacristallinita'.
ES2173280T3 (es) Composiciones pulverulentas y solubles en agua y sus aplicaciones.s
BR9916888A (pt) Uso de compostos e seus sais com ácidosfarmacologicamente aceitáveis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.